The authors thank Verena Bonn for the administrative support in data acquisition and analysis.
Supported by research grants of the Rudolf and Anna Katharina Eichenauer-Foundation, the German Research Foundation (Deutsche Forschungsgemeinschaft PF 950/1-1) and in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah.
Disclosure: M. Sassmannshausen, Heidelberg Engineering (F); Carl Zeiss Meditec (F); Optos (F); CenterVue (F); M. Pfau, Heidelberg Engineering (F); Carl Zeiss Meditec (C, F); Optos (F); CenterVue (F); S. Thiele, Heidelberg Engineering (F, R); Carl Zeiss Meditec (F); Optos (F); CenterVue (F); Bayer (R); Novartis (R); R. Fimmers, None; J. Steinberg, None; M. Fleckenstein, Heidelberg Engineering (F); Novartis (C, F); Roche/Genentech (C); US20140303013A1 (P); F. Holz, Acucela (C, F, R); Allergan (F, R); Appelis (C, R); Bayer (C, F, R); Boehringer-Ingelheim (C); Bioeq/Formycon (F, C); CenterVue (F); Ellex (R); Roche/Genentech (C, F, R); Geuder (C); Grayburg Vision (C, R); Heidelberg Engineering (C, F, R); Kanghong (C, F); LinBioscience (C, R); NightStarX (F); Novartis (C, F, R); Optos (F); Pixium Vision (C, F, R); Oxurion (C, R); Stealth BioTherapeutics (C, R); Carl Zeiss Meditec (F, R); S. Schmitz-Valckenberg, Acucela (F); Alcon/Novartis (C, F, R); Allergan (C, F, R); Bayer (F, R); Bioeq/Formycon (F, C); Carl Zeiss MedicTec (F, R); CenterVue (F); Galimedix (C); Genentech/Roche (F, R); Heidelberg Engineering (F); Katairo (F); Optos (F)